Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

264.92
+1.410.53%
Post-market: 265.050.1300+0.05%19:47 EDT
Volume:417.85K
Turnover:110.05M
Market Cap:17.54B
PE:20.44
High:265.50
Open:265.00
Low:260.00
Close:263.52
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:0.74
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:10.58
PE(LYR):-59.97

Loading ...

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Aug 31

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Aug 31

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Aug 31

HC Wainwright Initiates Coverage on Ascendis Pharma A/S With Buy Rating, $345 Price Target

MT Newswires Live
·
Aug 27

Ascendis Pharma initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Aug 27

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® CNP (Navepegritide) at Isds 2026

Reuters
·
Aug 26

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of Transcon® Cnp (Navepegritide) at Isds 2026

THOMSON REUTERS
·
Aug 26

Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside

Simply Wall St.
·
Aug 25

Ascendis Pharma Director Jean-Jacques Bienaime Buys USD 492,079 of Common Shares

Reuters
·
Aug 19

Eyconis Announces Initiation of First-in-Human Clinical Trial of Eyc-0305 in Treatment-NaÏVe Wet Age-Related Macular Degeneration Patients

THOMSON REUTERS
·
Aug 18

Ascendis Pharma A/S Just Recorded A 104% EPS Beat: Here's What Analysts Are Forecasting Next

Simply Wall St.
·
Aug 16

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

MT Newswires Live
·
Aug 14

Ascendis Pharma is Maintained at Overweight by Barclays

Dow Jones
·
Aug 14

Ascendis Pharma (ASND) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Aug 14

RBC Adjusts PT on Ascendis Pharma to $290 From $280, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
Aug 14

Ascendis Pharma (ASND) Receives a Buy from Wells Fargo

TIPRANKS
·
Aug 14

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ascendis Pharma (ASND)

TIPRANKS
·
Aug 14

Ascendis Pharma a/S : Jefferies Raises Target Price to $333 from $325

THOMSON REUTERS
·
Aug 14

Analysts Are Bullish on These Healthcare Stocks: ProMIS Neurosciences (PMN), Ascendis Pharma (ASND)

TIPRANKS
·
Aug 14